Cantargia obtains patent approval in Europe for the antibody CAN04 in development for treatment of cancer
Cantargia AB (”Cantargia”) today announced that the European Patent Office (“EPO”) has granted the company’s patent application on the product candidate CAN04. CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the intention to grant that EPO issued in April 2017.
The patent application with number 15714603.6 which was granted by the EPO, concerns the company’s product candidate CAN04. The patent protects CAN04 both as a substance as well for cancer treatment. The patent gives protection in Europe until 2035. In addition to the patent granted in Europe, a notice of allowance was obtained in the USA in June 2017. The application has also been submitted in a large number of additional territories such as Japan and China.
”A granted composition of matter patent in Europe is a central component in a commercialization strategy for CAN04”, says Göran Forsberg, CEO. “Cantargia is in a unique and strong position as we have granted patents both for our product candidate as well as the target molecule.”
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein “IL1RAP”, in leukemia stem cells, later research has also identified IL1RAP in a large number of other forms of cancer. The lead compound, CAN04 directed against IL1RAP, will be investigated in the CANFOUR phase I/IIa clinical trial in with primary focus on non-small lung cancer and pancreatic cancer. CAN04 has a dual mechanism of action, it blocks IL1RAP function and stimulates the immune system to eradicate tumor cells. Cantargia’s second project is in discovery phase with the goal to develop an IL1RAP binding antibody optimized for therapy of autoimmunity and inflammatory diseases.